Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-24-110979
Filing Date
2024-12-20
Accepted
2024-12-20 12:40:30
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 27910
2 SCHEDULE 1 ea022511501ex-1_bio.htm EX-1 17057
3 JOINT FILING AGREEMENT ea022511501ex99-1_bio.htm EX-99.1 6353
4 POWER OF ATTORNEY ea022511501ex99-4_bio.htm EX-99.2 5469
  Complete submission text file 0001213900-24-110979.txt   58445
Mailing Address ZIEGELHAUSER LANDSTRABE 1 HEIDELBERG 2M 691924-0
Business Address ZIEGELHAUSER LANDSTRABE 1 HEIDELBERG 2M 691924-0 49 6221 64727-0
DEUTSCHE BALATON AKTIENGESELLSCHAFT (Filed by) CIK: 0001571071 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A

Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Subject) CIK: 0001858685 (see all company filings)

EIN.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93395 | Film No.: 241566421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)